Sökning: id:"swepub:oai:gup.ub.gu.se/59472" >
Efficacy and safety...
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
-
Holgate, S. T. (författare)
-
Chuchalin, A. G. (författare)
-
Hebert, J. (författare)
-
visa fler...
-
- Lötvall, Jan, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för lungmedicin och allergologi,Institute of Internal Medicine, Dept of Respiratory Medicine/Allergology
-
Persson, G. B. (författare)
-
Chung, K. F. (författare)
-
Bousquet, J. (författare)
-
Kerstjens, H. A. (författare)
-
Fox, H. (författare)
-
Thirlwell, J. (författare)
-
Cioppa, G. D. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: Clin Exp Allergy. ; 34:4
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- BACKGROUND: Patients with severe asthma are often inadequately controlled on existing anti-asthma therapy, constituting an unmet clinical need. OBJECTIVE: This randomized, double-blind, placebo-controlled trial evaluated the ability of omalizumab, a humanized monoclonal anti-IgE antibody, to improve disease control sufficiently to enable inhaled corticosteroid reduction in patients with severe allergic asthma. METHODS: After a run-in period when an optimized fluticasone dose (> or =1000 microg/day) was received for 4 weeks, patients were randomized to receive subcutaneous omalizumab [minimum 0.016 mg/kg/IgE (IU/mL) per 4 weeks; n=126] or matching placebo (n=120) at intervals of 2 or 4 weeks. The study comprised a 16-week add-on phase of treatment followed by a 16-week fluticasone-reduction phase. Short-/long-acting beta(2)-agonists were allowed as needed. RESULTS: Median reductions in fluticasone dose were significantly greater with omalizumab than placebo: 60% vs. 50% (P=0.003). Some 73.8% and 50.8% of patients, respectively, achieved a > or =50% dose reduction (P=0.001). Fluticasone dose reduction to < or =500 microg/day occurred in 60.3% of omalizumab recipients vs. 45.8% of placebo-treated patients (P=0.026). Through both phases, omalizumab reduced rescue medication requirements, improved asthma symptoms and asthma-related quality of life compared to placebo. CONCLUSION: Omalizumab treatment improves asthma control in severely allergic asthmatics, reducing inhaled corticosteroid requirements without worsening of symptom control or increase in rescue medication use.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Holgate, S. T.
-
Chuchalin, A. G.
-
Hebert, J.
-
Lötvall, Jan, 19 ...
-
Persson, G. B.
-
Chung, K. F.
-
visa fler...
-
Bousquet, J.
-
Kerstjens, H. A.
-
Fox, H.
-
Thirlwell, J.
-
Cioppa, G. D.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Lungmedicin och ...
- Artiklar i publikationen
- Clin Exp Allergy
- Av lärosätet
-
Göteborgs universitet